These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 28673201)

  • 1. Health and budget impact of combined HIV prevention - first results of the BELHIVPREV model.
    Vermeersch S; Callens S; De Wit S; Goffard JC; Laga M; Van Beckhoven D; Annemans L
    Acta Clin Belg; 2018 Feb; 73(1):54-67. PubMed ID: 28673201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of antiretroviral therapy for the prevention of new HIV infection in populations at high risk for HIV sero-conversion in Nigeria.
    Idoko J; Folayan MO
    Afr J Reprod Health; 2014 Sep; 18(3 Spec No):127-34. PubMed ID: 26050385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of PrEP in HIV/AIDS control in Zambia: a stochastic league approach.
    Nichols BE; Baltussen R; van Dijk JH; Thuma PE; Nouwen JL; Boucher CA; van de Vijver DA
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):221-8. PubMed ID: 24694930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opportunities for improved HIV prevention and treatment through budget optimization in Eswatini.
    Minnery M; Mathabela N; Shubber Z; Mabuza K; Gorgens M; Cheikh N; Wilson DP; Kelly SL
    PLoS One; 2020; 15(7):e0235664. PubMed ID: 32701968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antiretroviral drugs-based HIV prevention methods: what impact on the HIV epidemic?].
    Supervie V
    Med Sci (Paris); 2013 Apr; 29(4):373-82. PubMed ID: 23621932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
    Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
    Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study.
    Cremin I; McKinnon L; Kimani J; Cherutich P; Gakii G; Muriuki F; Kripke K; Hecht R; Kiragu M; Smith J; Hinsley W; Gelmon L; Hallett TB
    Lancet HIV; 2017 May; 4(5):e214-e222. PubMed ID: 28233660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From modeling to morals: imagining the future of HIV PREP in Lesotho.
    Kenworthy NJ; Bulled N
    Dev World Bioeth; 2013 Aug; 13(2):70-8. PubMed ID: 23800326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical online tool to estimate antiretroviral coverage for HIV infected and susceptible populations needed to reduce local HIV epidemics.
    Chaillon A; Hoenigl M; Mehta SR; Weibel N; Little SJ; Smith DM
    Sci Rep; 2016 Jun; 6():28707. PubMed ID: 27337983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the impact of increasing condom use or HIV pre-exposure prophylaxis (PrEP) use among female sex workers.
    Mukandavire Z; Mitchell KM; Vickerman P
    Epidemics; 2016 Mar; 14():62-70. PubMed ID: 26972515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low knowledge of antiretroviral treatments for the prevention of HIV among precarious immigrants from sub-Saharan Africa living in the greater Paris area: Results from the Makasi project.
    Coulibaly K; Gosselin A; Carillon S; Taéron C; Mbiribindi R; Desgrées Du Loû A;
    PLoS One; 2023; 18(6):e0287288. PubMed ID: 37315089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans.
    Spinner CD; Boesecke C; Zink A; Jessen H; Stellbrink HJ; Rockstroh JK; Esser S
    Infection; 2016 Apr; 44(2):151-8. PubMed ID: 26471511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the impact of state budget cuts and redirection of prevention resources on the HIV epidemic in 59 California local health departments.
    Lin F; Lasry A; Sansom SL; Wolitski RJ
    PLoS One; 2013; 8(3):e55713. PubMed ID: 23520447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "In reality, it is complex and difficult": UK nurses' perspectives on "treatment as prevention" within HIV care.
    Evans C; Bennett J; Croston M; Brito-Ault N; Bruton J
    AIDS Care; 2015; 27(6):753-7. PubMed ID: 25650545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethics of ARV based prevention: treatment-as-prevention and PrEP.
    Haire B; Kaldor JM
    Dev World Bioeth; 2013 Aug; 13(2):63-9. PubMed ID: 23594312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of HIV prevention for high-risk groups at scale: an economic evaluation of the Avahan programme in south India.
    Vassall A; Pickles M; Chandrashekar S; Boily MC; Shetty G; Guinness L; Lowndes CM; Bradley J; Moses S; Alary M; ; Vickerman P
    Lancet Glob Health; 2014 Sep; 2(9):e531-e540. PubMed ID: 25304420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?
    Verguet S; Stalcup M; Walsh JA
    Sex Transm Infect; 2013 Dec; 89(8):628-34. PubMed ID: 23912819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating HIV prevention and treatment: from slogans to impact.
    Salomon JA; Hogan DR; Stover J; Stanecki KA; Walker N; Ghys PD; Schwartländer B
    PLoS Med; 2005 Jan; 2(1):e16. PubMed ID: 15647780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress and prospects for the control of HIV and tuberculosis in South Africa: a dynamical modelling study.
    Williams BG; Gupta S; Wollmers M; Granich R
    Lancet Public Health; 2017 May; 2(5):e223-e230. PubMed ID: 29253488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pre-exposure prophylaxis for HIV: a review.
    Schackman BR; Eggman AA
    Curr Opin HIV AIDS; 2012 Nov; 7(6):587-92. PubMed ID: 23076124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.